Sanofi France Chief Bogillot sees pandemic vaccine priced below €10



by   |  VIEW 849

Sanofi France Chief Bogillot sees pandemic vaccine priced below €10

As Government agencies and drugmakers have been galloping through to come up with a pandemic vaccine, in an interview with France Inter radio, Paris-headquartered world’s fifth-largest pharmaceutical Sanofi’s Chief in France said on Saturday that a vaccine for the pandemic outbreak which it was developing with British drugmaker GlaxoSmithKline might be priced below €10 per shot if approved.

Nonetheless, adding that the prices could vary as the company had been assessing the production costs, Olivier Bogillot, the Chief Exec. of Sanofi in France said in the interview with France Inter radio, “The price is not totally set ...

We are assessing production costs for the coming months ... We will be below 10 euros.

Sanofi sees pandemic vaccine below €10; AstraZeneca to price €2.5

Aside from that, while being asked on its rival AstraZeneca’s pricing strategy which has been expected to unveil its vaccines for the pandemic outbreak below €2.50 for Europe, underscoring that AstraZeneca’s production line remained largely dependent on outsourcing that could compromise the quality, Bogillot said in the France Inter radio interview aired on Saturday, “The price gap for us can be that we use all our internal resources, our own researchers, our own research centres.

AstraZeneca outsources part of its production. We anticipate being able to determine a final price at the time of our Phase III trials, when we know more about dosing. At this stage, any figure is imprecise. Less than 10 euros is only one of the hypotheses we are working on.

” In tandem, a Sanofi spokeswoman was quoted saying in an emailed statement shortly after the France Inter radio interview had been aired on Saturday that a final pricing could be decided following a Phase III human clinical trial of the Sanofi-GSK vaccine.

Earlier this week, Sanofi and GSK had said in a joint statement that they had started off a clinical trial of their protein-based pandemic vaccine, while the heavyweight drugmakers have been expecting to reach the Phase III stage of the trial by end-2020.